Selecta Biosciences logo
Selecta Biosciences SELB

Annual report 2025
added 03-09-2026

report update icon

Selecta Biosciences Financial Statements 2011-2026 | SELB

Annual Financial Statements Selecta Biosciences

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- - 135 M 232 M 212 M 427 M 137 M 39 M 193 M 150 M - - - - -

Shares

26 M 17.3 M 155 M 145 M 114 M 101 M 45.5 M 22.4 M 20.4 M 10.5 M - - - - -

Historical Prices

- - 0.87 1.6 1.85 4.22 4 1.99 9.16 13.1 - - - - -

Net Income

-130 M -77.4 M -220 M 35.4 M -25.7 M -68.9 M -55.4 M -65.3 M -65.3 M -36.2 M -25.2 M -12.9 M - - -

Revenue

2.8 M 38.9 M 26 M 111 M 85.1 M 16.6 M 6.68 M 903 K 207 K 8.08 M 6.01 M 3.04 M - - -

Operating Income

-143 M -43.9 M -86.4 M 14.5 M -4.6 M -56.8 M -52.5 M -65 M -63.8 M -34.7 M -25.3 M -15.4 M - - -

Interest Expense

-2.01 M 606 K 2.83 M 3.03 M 2.84 M 1.56 M 1.52 M 1.49 M 1.21 M 1.25 M 948 K 552 K - - -

EBITDA

-141 M -42.7 M -85.7 M 15.2 M -4 M -56.2 M -50.4 M -64 M -63 M -33.9 M -24.3 M -14.5 M - - -

Operating Expenses

146 M 82.8 M 112 M 96.2 M 89.7 M 73.4 M 59.1 M 65.9 M 64 M 42.8 M - - - - -

General and Administrative Expenses

31.5 M 30.1 M 40.6 M 23.9 M 20.9 M 18.9 M 16.4 M 18.2 M 18.8 M 13.1 M 8.34 M 7.95 M - - -

All numbers in USD currency

Quarterly Income Statement Selecta Biosciences

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

26 M 26 M 25.9 M 25.8 M 21.5 M 16.7 M 5.41 M 5.4 M 5.16 M 5.11 M 5.11 M 153 M 153 M 149 M 124 M 124 M 115 M 114 M 111 M 108 M 105 M 96.8 M 94.7 M 86.3 M 46.4 M 44.9 M 38.4 M 22.5 M 22.4 M 22.4 M 22.3 M 22.3 M 22.1 M 18.8 M 18.5 M 18.3 M 18.1 M 3.32 M 2.18 M 2.17 M 2.16 M 2.15 M 2.13 M - - - - - - - - - - - - - - - -

Net Income

-35.9 M 15.9 M -17.7 M - -24.2 M 13.8 M -56.8 M - -9 M -11.4 M -21.7 M - -7.89 M 8.6 M 28.8 M - -17.9 M 4.56 M -24.6 M - -9.73 M -24.1 M -19.6 M -14.9 M -12 M -16.4 M -12.1 M -14.7 M -16 M -18.8 M -15.9 M -19.5 M -14.7 M -16 M -15.1 M -14.1 M -7.73 M -6.92 M -7.48 M -6.85 M -5.72 M -6.87 M -5.73 M - - - - - - - - - - - - - - - -

Revenue

452 K 298 K 1.1 M - 387 K 33.4 M 5.84 M - 6.55 M 5.25 M 5.94 M - 20.7 M 39.3 M 34 M - 24.4 M 19.7 M 11 M - 4.65 M - - 6.65 M - 13 K 10 K 903 K - - - 17 K 27 K 26 K 137 K 2.93 M 1.05 M 2.02 M 2.09 M 2.13 M 1.61 M 1.24 M 1.03 M - - - - - - - - - - - - - - - -

Operating Income

-21.1 M -21.8 M -21.9 M - -17.6 M 13.8 M -13.3 M - -13.1 M -18.6 M -18.4 M - -1.6 M 13.9 M 10.8 M - -1.97 M 452 K -7.16 M - -13.7 M -16.4 M -18.8 M - -11.8 M -16.2 M -11.9 M - -15.9 M -18.8 M -15.8 M - -13.9 M -15.9 M -14.8 M - -7.47 M -6.4 M -6.94 M - -6.07 M -6.32 M - - - - - - - - - - - - - - - - -

Interest Expense

- -5 K - - 250 K 292 K 508 K - 253 K 245 K 808 K - 802 K 715 K 707 K - 711 K 711 K 711 K - 365 K 205 K 273 K - 388 K 400 K 396 K - 384 K 365 K 350 K - 268 K 279 K 300 K - 311 K 310 K 310 K - 334 K 330 K - - - - - - - - - - - - - - - - -

EBITDA

-20.5 M -21.2 M -21.3 M - -17.3 M 14 M -13.1 M - -13 M -18.4 M -18.2 M - -1.4 M 14.1 M 10.9 M - -1.87 M 652 K -7.06 M - -13.6 M -16.2 M -18.6 M - -11.6 M -16 M -11.7 M - -15.7 M -18.4 M -15.6 M - -13.7 M -15.7 M -14.6 M - -7.37 M -6.2 M -6.76 M - -5.87 M -5.82 M - - - - - - - - - - - - - - - - -

Operating Expenses

21.5 M 22.1 M 23 M - 18 M 19.7 M 19.2 M - 19.6 M 23.9 M 24.3 M - 22.3 M 25.4 M 23.2 M - 26.4 M 19.2 M 18.2 M - 18.4 M 16.4 M 18.8 M 19.2 M 11.8 M 16.2 M 11.9 M 15.4 M 15.9 M 18.8 M 15.8 M 19.3 M 13.9 M 15.9 M 14.9 M 16.8 M 8.52 M 8.42 M 9.03 M 9.24 M 7.68 M 7.55 M 6.84 M - - - - - - - - - - - - - - - -

General and Administrative Expenses

7.72 M 7.24 M 8.32 M - 6.56 M 7.03 M 9.45 M - 6.61 M 6.1 M 5.7 M - 5.77 M 6.23 M 5.54 M - 5.44 M 4.75 M 5.2 M - 4.42 M 5.64 M 4.1 M - 3.69 M 4.11 M 4.51 M - 4.06 M 4.36 M 4.67 M - 4.38 M 4.9 M 3.88 M - 2.5 M 2.42 M 2.38 M - 2.2 M 2.24 M - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Selecta Biosciences SELB
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Selecta Biosciences plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.14 0.36 % $ 443 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.41 4.73 % $ 230 M israelIsrael
Ardelyx Ardelyx
ARDX
$ 6.06 1.94 % $ 1.46 B usaUSA
argenx SE argenx SE
ARGX
$ 752.35 0.79 % $ 25 B niderlandNiderland
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.83 0.85 % $ 3.03 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.65 -1.12 % $ 16.6 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
BioCardia BioCardia
BCDA
$ 1.2 -0.04 % $ 8 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 9.6 6.37 % $ 1.98 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 9.48 -3.27 % $ 613 M usaUSA
BioVie BioVie
BIVI
$ 1.45 2.09 % $ 2.14 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.32 4.98 % $ 908 M israelIsrael
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 56.49 1.78 % $ 10.8 B usaUSA
BioNTech SE BioNTech SE
BNTX
$ 92.3 1.23 % $ 27.2 B germanyGermany
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 3.04 1.54 % $ 259 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.16 -2.12 % $ 14.2 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.54 9.54 % $ 683 M britainBritain
Cabaletta Bio Cabaletta Bio
CABA
$ 3.2 7.94 % $ 322 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.21 4.56 % $ 6.98 B israelIsrael
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 19.97 2.94 % $ 1.78 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Codexis Codexis
CDXS
$ 1.97 7.97 % $ 172 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 1.91 2.42 % $ 364 M usaUSA
Cullinan Management Cullinan Management
CGEM
$ 15.4 6.72 % $ 928 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.75 0.87 % $ 205 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain